Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05269160 · ClinicalTrials.gov registry record · Phase 1
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
A Phase 1 study, sponsored by Baylor College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05269160 is a Phase 1 study that was terminated before completion, run by Baylor College of Medicine. The registered enrollment target is 3 participants.
The verdict
NCT05269160, a Phase 1 study, was terminated before completion, sponsored by Baylor College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity. The aim of this study is to investigate the safety and tolerability (Phase I) and preliminary efficacy (Phase II) of prophylactic esomeprazole cream (termed "Dermaprazole") in patients who require radiation for breast cancer in the adjuvant setting.
Interventions
- DRUG Dermaprazole 1%
- DRUG Dermaprazole 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05269160
The ClinicalTrials.gov registry entry for NCT05269160 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dermaprazole 1% is the first listed.
NCT05269160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05269160 about?
NCT05269160 is a clinical study titled "Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)". Radiotherapy is a mainstay of treatment in breast cancer treatment, in the adjuvant setting. Radiation dermatitis occurs in up to 65% of these patients; currently, there is no standard of care for this treatment-related toxicity. The aim of this study is to investigate the safety and tolerability (P...
What is the current status of trial NCT05269160?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-04-24. Estimated completion is 2024-04-15.
What interventions are being tested in trial NCT05269160?
The interventions under investigation include: Dermaprazole 1% (DRUG), Dermaprazole 2% (DRUG).
Who is sponsoring clinical trial NCT05269160?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.